Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Leveraging the pharmacy executive beyond the pharmacy enterprise: Opportunities for advocacy, senior leadership integration, and strategic positioning.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2021

Same author

Iron deficiency anemia in women: a practical guide to detection, diagnosis, and treatment.

Obstetrical & gynecological survey·2015

Same author

Iron deficiency anemia--bridging the knowledge and practice gap.

Transfusion medicine reviews·2014

Same author

Accountable care organizations: impact on pharmacy.

Hospital pharmacy·2014

Same author

Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).

Current medical research and opinion·2013

Same author

Optimizing anemia management through medication reconciliation: applying the 2010 joint commission patient safety goal requirements.

P & T : a peer-reviewed journal for formulary management·2010

Search research articles

Related Experiment Video

Updated: May 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Managed care implications in castration-resistant prostate cancer.

¹1 Cragwood Rd, Suite 3D, South Plainfield, NJ 07080.

The American Journal of Managed Care

|February 6, 2014

Summary

Managing advanced prostate cancer (PrCa) is complex and costly. New targeted therapies improve survival for castration-resistant prostate cancer (CRPC), but require careful cost and utilization analysis for effective patient management.

Area of Science:

Oncology
Health Economics

Background:

Prostate cancer (PrCa) management, particularly castration-resistant PrCa (CRPC), presents significant clinical and economic challenges.
Recent advancements in oncology have introduced novel, targeted therapies for CRPC, improving patient survival outcomes.
The emergence of new treatments necessitates a thorough evaluation of their associated costs and impact on healthcare utilization.

Purpose of the Study:

To analyze the economic burden and healthcare utilization associated with prostate cancer, with a specific focus on castration-resistant disease in the United States.
To inform managed care clinicians and providers about the financial and logistical aspects of managing CRPC.
To facilitate a better understanding of how cost and utilization influence individualized treatment and management decisions for CRPC patients.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: May 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Murine Prostate Micro-dissection and Surgical Castration

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Main Methods:

This study involves an analysis of existing data on the costs and healthcare utilization patterns for prostate cancer patients.
The research focuses on evaluating the economic impact of newly approved therapies for castration-resistant prostate cancer.
A review of treatment paradigms and their associated financial implications is conducted.

Main Results:

The introduction of five new therapies has demonstrated increased overall survival for patients with castration-resistant prostate cancer.
These new treatment options introduce new management strategies and potential cost implications for the healthcare system.
Understanding the financial toxicity and resource allocation is crucial for optimizing CRPC care.

Conclusions:

Effective management of prostate cancer, especially CRPC, requires a comprehensive understanding of both clinical efficacy and economic factors.
Managed care providers must analyze the cost-effectiveness and utilization of new CRPC therapies to ensure sustainable and equitable patient care.
Individualized treatment decisions for CRPC should integrate clinical benefits with economic considerations and healthcare resource management.